^
Association details:
| Biomarker: | TNFRSF17 deletion |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
Published date:
02/22/2021
Excerpt:
We report a case of irreversible BCMA loss in a patient with MM...progressed after anti-BCMA CAR T cell therapy...we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.
DOI:
10.1038/s41591-021-01245-5
Trial ID:
